Search 

Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages.  KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.

KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features.  KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.

Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics.  The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device.   Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization

Laureate Biopharma is a leader in biopharmaceutical contract development and manufacturing with more than 30 years of experience. Our scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, our portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and full regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981. Laureate is a portfolio company of Saints Capital, LLC.

MacroGenics is a leader in the development of next-generation antibody therapeutics for the treatment of cancer, autoimmune disorders, and infectious disease. Using its proprietary platforms for cancer-stem cells, bi-specific antibodies (DARTs) and Fc-optimization, the company has generated a robust pipeline of clinical and pre-clinical programs. The company has multiple research and development collaborations with major pharmaceutical companies including Les Laboratoires Servier, Boehringer Ingelheim and Pfizer, Inc.

Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions.  Covidien announced last December that they are spinning off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.  Mallinckrodt is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems.  Sales in 2011 were $2.0 billion. Please visit www. mallinckrodt.com to learn more about our business.  The company’s branded pharmaceuticals portfolio includes EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID® (diclofenac sodium topical solution) 1.5% w/w.  In June 2012, Mallinckrodt entered into agreements with Horizon Pharma and Zogenix Inc. to co-promote their branded pharmaceuticals for rheumatoid arthritis and acute migraine, respectively.  In August 2012, the FDA approved the 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII).  Mallinckrodt is primarily pursuing acquisition or licensing deals for pharmaceuticals which are either in late stage development or are approved for commercialization.

MannKind’s patient-focused oral inhalation drug delivery technologies include a dry powder formulation capability coupled with an innovative, elegant, breath-powered delivery device. We are applying these technologies to facilitate partnered drug development programs for proprietary compounds.

MannKind has numerous collaborations across therapeutic areas that demonstrate the efficacy and safety of the technologies. Patients self-administer these dry powder formulations with small, easy-to-use, breath-powered inhalers. Following inhalation, drugs are absorbed very rapidly, essentially mimicking intra-arterial administration. MannKind has evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, respiratory disease, osteoporosis and pain.

For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind offers a feasibility evaluation. These evaluations involve preparation and characterization of API/Technosphere formulations. These powders are tested for performance in MannKind’s inhalers. Additionally, MannKind works with the partner to test these powders in relevant nonclinical PK/PD models. These studies can often been completed within 6 months. 

MannKind seeks to establish partnerships to build therapeutic programs of significant clinical and commercial value. Whether through strategic alliances, licensing arrangements and/or research collaborations, MannKind's partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticalshas entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.

Meda is a global specialty pharma company with products in over 120 countries worldwide and $1.9BUSD in sales.

Meda's primary growth strategy is search and acquire focusing on acquisitions aligned with our current verticals (allergy/respiratory; women and men's health; dermatology (EU); cardiovascular (EU); and pain and inflammation).

We tend towards low risk investments, hence, late stage products (e.g., successful completion of a Phase III) or marketed products. We avoid 505(b)(2) products unless there is a clear unmet need that is met by a highly differentiated product.